“Pharma Wholesale and Distribution market set to grow to $1,447bn by 2025” says new Visiongain report

01 October 2019
Pharma

Visiongain has launched a new pharma report: Pharma Wholesale and Distribution Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.

The pharmaceutical wholesale and distribution market is influenced by the play of a variety of factors; it has both strengths and weaknesses and faces both opportunities and threats. The market will be driven by an overall increased demand for pharmaceuticals owing to the growing ageing population of developed countries and the increasing access to healthcare of the expanding middle class in the emerging economies.

The lead analyst of the report commented "Over the course of the forecast period, all national pharmaceutical wholesale and distribution markets discussed in this report will experience growth. However, this growth will be significantly faster in emerging markets, such as China. Growth will be faster in these emerging markets as it mirrors growth in the pharmaceutical markets; demand for prescription pharmaceuticals will become much higher in developing countries."

Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Cardinal Health, McKesson, Medipal, PHOENIX Group, Shanghai Pharma, SINOPHARM, Suzuken, Walgreens Boots Alliance and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

Read

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

Read

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

Read

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever